Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease.

Matthew R RosebraughEric A VoightEhab M MoussaFeroz JameelXiaochun LouGeoff G Z ZhangPeter T MayerDeanne StolarikRobert A CarrBrian P EnrightWei LiuMaurizio F FacherisPhilip R Kym

Published in: Annals of neurology (2021)

Preparation of foslevodopa and foscarbidopa enables preclinical and clinical PK, safety, and tolerability studies in support of their advancement for the treatment of PD. In phase 1 clinical trials, foslevodopa/foscarbidopa demonstrates consistent and stable LD plasma exposure, supporting further studies of this treatment as a potentially transformational option for those suffering from PD. ANN NEUROL 2021;90:52-61.

Keyphrases

clinical trial
stem cells
randomized controlled trial
high resolution
mass spectrometry
replacement therapy
study protocol
cell therapy
phase ii